Log in to search using one of your social media accounts:

 

An IIT solution to 'expensive' biotechnology
Trastuzumab, a drug developed through bio-engineering, currently has a maximum retail price of Rs 52,000-58,602 for a 440 mg vial, depending on the brand, according to the National Pharmaceutical Pricing Authority. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 20, 2017 Category: Pharmaceuticals Source Type: news

Trastuzumab Use, on Its Own, Should Not Delay Post-surgical Breast Reconstruction Trastuzumab Use, on Its Own, Should Not Delay Post-surgical Breast Reconstruction
Breast reconstruction after cancer surgery doesn't need to be delayed if the patient is taking trastuzumab, new research suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 17, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Trastuzumab treatment need not delay breast reconstruction following mastectomy
(American College of Surgeons) Treatment with trastuzumab (Herceptin/Genentech) of breast cancers that express the HER-2 protein does not increase the risk for complications at the surgical site for women who undergo immediate breast reconstruction after mastectomy. The first study to assess the effect of trastuzumab on surgical wound complications indicates that breast reconstruction need not be delayed because of the type or length of this form of adjuvant therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 3, 2017 Category: International Medicine & Public Health Source Type: news

Roche's Perjeta regimen gets FDA priority review in breast cancer
ZURICH (Reuters) - The U.S. Food and Drug Administration (FDA) has granted priority review for Roche's Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery, Roche said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - September 29, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA grants Priority Review for Roche ’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer
Roche today announced the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Perjeta® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast cancer (eBC). The FDA is exp ected to make a decision on approval by 28 January 2018. (Source: Roche Media News)
Source: Roche Media News - September 29, 2017 Category: Pharmaceuticals Source Type: news

FDA grants Priority Review for Roche ’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer
Roche today announced the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Perjeta® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast cancer (eBC). The FDA is exp ected to make a decision on approval by 28 January 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - September 29, 2017 Category: Pharmaceuticals Source Type: news

Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress
Study Between ABP 980 and Trastuzumab in Patients With HER2-Positive Early Breast Cancer Adds to the Totality of Evidence of Biosimilarity THOUSAND OAKS, Calif. and DUBLIN, Sept. 9, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced data from a Phase 3 study evaluating the efficacy and safety of ABP 980, a Herceptin® (trastuzumab) biosimilar, compared with the originator product in patients with human epidermal growth factor receptor 2-positive (HER2-positive) early breast cancer. Results from the neoadjuvant efficacy phase of the study, including pathologic complete response ass...
Source: Amgen News Release - September 9, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Breast cancer biosimilar approval delayed as US FDA reviews additional information by Biocon, Mylan
Biocon and Mylan have together developed the trastuzumab biosimilar, which is a copy of a complex biologic drug developed by Swiss biotech giant Roche. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 30, 2017 Category: Pharmaceuticals Source Type: news

FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's DS-8201 for HER2-Positive Metastatic Breast Cancer
Breakthrough Therapy designation received for the treatment of patients with HER2-positive, locally advanced or metastatic breast cancer who have been treated with trastuzumab and pertuzumab and have disease progression after ado-trastuzumab emtansine (T-D... Biopharmaceuticals, Oncology, FDA Daiichi Sankyo, Breakthrough Therapy, DS-8201, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 29, 2017 Category: Pharmaceuticals Source Type: news

Case Closed on < 1 Year of Herceptin for Breast Cancer Case Closed on < 1 Year of Herceptin for Breast Cancer
For early-stage breast cancer, the treatment duration of 1 year for trastuzumab was a guess. New research indicates it was a good guess.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 25, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Case Closed on < 1 Year of Trastuzumab for Breast Cancer Case Closed on < 1 Year of Trastuzumab for Breast Cancer
For early-stage breast cancer, the treatment duration of 1 year for trastuzumab was a guess. New research indicates it was a good guess.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 25, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Biocon pulls application for EU approval of two drugs
Biocon will re-submit the applications for breast cancer drug Trastuzumab and Pegfilgrastim, which cuts infection risk in patients undergoing chemotherapy. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 16, 2017 Category: Pharmaceuticals Source Type: news

Trastuzumab for six months cost  effective in Iran
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2017 Category: Drugs & Pharmacology Source Type: news

Amgen and Allergan Submit Biosimilar Biologics License Application for ABP 980 to US Food and Drug Administration
Filing for ABP 980, a Biosimilar Candidate to Herceptin® (trastuzumab), Supported by Phase 3 Data in Patients With HER2-Positive Early Breast Cancer THOUSAND OAKS, Calif., July 31, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AM... Biopharmaceuticals, Generics, Oncology, FDA Amgen, Allergan, ABP 980, Herceptin, (trastuzumab, Genentech, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 31, 2017 Category: Pharmaceuticals Source Type: news

Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 980 To US Food And Drug Administration
Filing for ABP 980, a Biosimilar Candidate to Herceptin® (trastuzumab), Supported by Phase 3 Data in Patients With HER2-Positive Early Breast Cancer THOUSAND OAKS, Calif., July 31, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 980, a biosimilar candidate to Herceptin® (trastuzumab). Amgen and Allergan are collaborating on four oncology biosimilar medicines, including ABP 980 which is the second to be submitted for FDA approval. "The submission of AB...
Source: Amgen News Release - July 31, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Panel Backs Trastuzumab Biosimilar
The FDA Oncologic Drugs Advisory Committee has unanimously voted to recommend approval of the trastuzumab biosimilar MYL-1401O for the treatment of HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 27, 2017 Category: Cancer & Oncology Authors: Ian Ingram Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

Roche, Emcure may end pact to make 2 blockbuster drugs
Emcure is still the distributor for those two drugs in India. Roche had handed out the manufacturing and marketing of trastuzumab and rituximab to Pune-based Emcure. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 24, 2017 Category: Pharmaceuticals Source Type: news

FDA OKs First'Extended' Adjuvant Treatment for HER2 Breast Cancer FDA OKs First'Extended' Adjuvant Treatment for HER2 Breast Cancer
The FDA has approved a new drug for patients with early-stage HER2-positive breast cancer who have completed trastuzumab and want"extended" adjuvant therapy.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 17, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA approves new treatment to reduce the risk of breast cancer returning
The U.S. Food and Drug Administration today approved Nerlynx (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer. For patients with this type of cancer, Nerlynx is the first extended adjuvant therapy, a form of therapy that is taken after an initial treatment to further lower the risk of the cancer coming back. Nerlynx is indicated for adult patients who have been previously treated with a regimen that includes the drug trastuzumab. (Source: Food and Drug Administration)
Source: Food and Drug Administration - July 17, 2017 Category: American Health Source Type: news

Biosimilars to Avastin and Herceptin Head for US Market Biosimilars to Avastin and Herceptin Head for US Market
Two new biosimilars, bevacizumab and trastuzumab, were unanimously recommended for approval by an FDA oncologic advisory committee.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 14, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Biosimilars Get Clean Sweep at FDA Hearings
(MedPage Today) -- Unanimous backing for Herceptin biosimilar; follows identical vote for Avastin copy (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 13, 2017 Category: American Health Source Type: news

Are Biobetters Better?
Biosimilars and biobetters are both variants of a biologic drug, however, while biosimilars are close copies of the originator, biobetters have been improved, for example, in terms of efficacy, safety, tolerability or dosing regimen.Regulators consider biobetters as new products and so afford them the same patent protection as any originator, however, this means they require the same clinical and non-clinical data packages. Conversely, a reduced clinical data package is an attractive element for the development of biosimilars.Given the cost of development and the time pressure to bring a biobetter to market before biosimil...
Source: EyeForPharma - July 3, 2017 Category: Pharmaceuticals Authors: James Wright Source Type: news

Long-Term Data Confirm TH Benefit in Early HER2-Positive Breast Cancer
This video highlights 7-year follow-up data from the APT trial, which studied adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 30, 2017 Category: Cancer & Oncology Authors: Sara M. Tolaney, MD, MPH Tags: News Videos Breast Cancer Source Type: news

Biosimilar for HER2-Positive Breast Cancer Equivalent to Trastuzumab
A biosimilar to trastuzumab known as CT-P6 showed equivalent efficacy and similar toxicity to the original agent in patients with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 26, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

In a world ruled by rumour, it is vital that scientists speak with humility and clarity | Sue Desmond-Hellmann
Facts are the science world ’s stock-in-trade, but in an era of fake news it is ever more important to build public trust by avoiding exaggerated claims and jargonOne of my most cherished possessions is a handmade cherrywood salad bowl that ’s never held a leaf of lettuce. It is 25 years old and gets more beautiful every year. The bowl was a gift, carved by a widower who was left to raise his daughter alone when his wife died under my care as an oncologist. My patient, who I’ll call Erica, had the most challenging form of breast ca ncer and I didn’t have the tools to save her life. I’ve always...
Source: Guardian Unlimited Science - June 23, 2017 Category: Science Authors: Sue Desmond-Hellmann Tags: Global development Science Science and scepticism World news Climate change Source Type: news

UC consortium formed to speed up development of new drugs
For 12 years, UCLA researcher Dennis Slamon pursued a groundbreaking approach to treating breast cancer: Attack the disease genetically.The journey was long and filled with obstacles, but his persistence paid off.Slamon and colleagues conducted laboratory and clinical research that, in collaboration with biotechnology firm Genentech, helped lead to development of the breast cancer drug Herceptin.UCLA's Dennis Slamon with Harry Connick Jr., who played the professor of medicine in a 2008 television movie.The drug, which targets a specific genetic alteration found in about 25 percent of breast cancer patients, has saved thous...
Source: UCLA Newsroom: Health Sciences - June 21, 2017 Category: Universities & Medical Training Source Type: news

NICE set to approve trastuzumab emtansine for breast cancer
NHS England will routinely fund Kadcyla for people with advanced HER-2 positive cancer Related items fromOnMedica Ovarian cancer drug may help stall breast cancer The medicine price debate Breast cancer drug ‘too costly’ for NHS Experts recommend anastrozole for postmenopausal women with family history of breast cancer Cancer-preventing drugs (Source: OnMedica Latest News)
Source: OnMedica Latest News - June 16, 2017 Category: UK Health Source Type: news

Advanced breast cancer drug to become routinely available
A “landmark” deal has been announced on the breast cancer drug trastuzumab emtansine (Kadcyla), meaning that it can now be recommended for routine use by the NHS in England. (Source: Nursing Times)
Source: Nursing Times - June 15, 2017 Category: Nursing Source Type: news

Two Anti-HER2 Drugs Slightly Better Than One
(MedPage Today) -- Patient selection key to addition of pertuzumab to trastuzumab (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 7, 2017 Category: Hematology Source Type: news

Pertuzumab Combo Improved Invasive DFS in HER2-Positive Breast Cancer
The addition of pertuzumab to trastuzumab and chemotherapy improved invasive disease –free survival in patients with HER2-positive early breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO Breast Cancer HER2-Positive Breast Cancer News Source Type: news

Trastuzumab Copycat Has Similar Efficacy
(MedPage Today) -- Phase III trial compared substances in early-stage breast cancer (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - June 5, 2017 Category: General Medicine Source Type: news

Is APHINITY the End of the Line for Trastuzumab Add-ons? Is APHINITY the End of the Line for Trastuzumab Add-ons?
The addition of pertuzumab to standard trastuzumab therapy in patients with early HER2-positive breast cancer led to modest improvements and increased side effects in the APHINITY trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 5, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Drugs Score Big Wins Against Lung, Prostate, Breast Cancers
CHICAGO (AP) — Drugs are scoring big wins against common cancers, setting new standards for how to treat many prostate, breast and lung tumors. There’s even a “uni-drug” that may fight many forms of the disease. What’s striking: The drugs are beneficial in some cases for more than a year, much longer than the few months many new drugs provide. Here are highlights from the world’s largest cancer meeting, the American Society of Clinical Oncology conference in Chicago. PROSTATE CANCER Janssen Biotech’s Zytiga improved survival and delayed cancer growth for 18 months when added to sta...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 5, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Breast Cancer Health News Prostate Cancer Source Type: news

Roche suffers blow over breast cancer combination therapy
Large trial shows only marginal benefit from taking cocktail of Herceptin and Perjeta (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - June 5, 2017 Category: Pharmaceuticals Source Type: news

APHINITY study shows Roche ’s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer
Roche, the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS) today announced the Phase III APHINITY study showed adjuvant (after surgery) treatment with the combination of Perjeta ® (pertuzumab), Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) significantly reduced the risk of breast cancer recurrence or death (invasive disease-free survival; iDFS) by 19% in people with HER2-positive early breast cancer (eBC) compared to Herceptin and chemotherapy alon e (HR=0.81; 95% CI 0.66-1.00, p=0.045). (Source: Roche Media News)
Source: Roche Media News - June 5, 2017 Category: Pharmaceuticals Source Type: news

APHINITY study shows Roche ’s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer
Roche, the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS) today announced the Phase III APHINITY study showed adjuvant (after surgery) treatment with the combination of Perjeta ® (pertuzumab), Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) significantly reduced the risk of breast cancer recurrence or death (invasive disease-free survival; iDFS) by 19% in people with HER2-positive early breast cancer (eBC) compared to Herceptin and chemotherapy alon e (HR=0.81; 95% CI 0.66-1.00, p=0.045). (Source: Roche Investor Update)
Source: Roche Investor Update - June 5, 2017 Category: Pharmaceuticals Source Type: news

Adding a second HER2 blocker may lower chance of invasive breast cancer for some women
(American Society of Clinical Oncology) A phase III clinical trial of 4,805 women with HER2-positive breast cancer suggests adding a second HER2 targeted medicine, pertuzumab (Perjeta), to standard of care trastuzumab (Herceptin) after surgery may help, although the benefit is modest. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 5, 2017 Category: Cancer & Oncology Source Type: news

Biosimilar May Be As Effective as Trastuzumab for Early Breast Cancer (FREE)
By Kelly Young Edited by Susan Sadoughi, MD, and Andr é Sofair, MD, MPH Biosimilar trastuzumab appears to have a similar effect on HER2-positive, early-stage breast cancer as standard trastuzumab (Herceptin), according … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 5, 2017 Category: Primary Care Source Type: news

Final TH3RESA, EMILIA Results Confirm Role of Trastuzumab Emtansine in HER2+ Breast Cancer
Final results from two large phase III trials confirm that the drug-antibody conjugate trastuzumab emtansine improves overall survival over other treatment options in patients with previously treated HER2-positive metastatic breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 25, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

Herceptin (Trastuzumab) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 22, 2017 Category: Drugs & Pharmacology Source Type: news

Vinorelbine, Pertuzumab, and Trastuzumab for Breast Cancer Vinorelbine, Pertuzumab, and Trastuzumab for Breast Cancer
Is the combination of vinorelbine with dual HER2-targeted therapy a good first-line option for patients needing an alternative to docetaxel?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 27, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

RT Plus Trastuzumab Have Little Effect on LVEF in HER2+ Breast Cancer
Trastuzumab plus low-dose radiotherapy does not have a significant effect on left ventricular ejection fraction changes in HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - April 20, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

Dual HER2 Blockade Promising in HER2-Positive Metastatic CRC
Dual HER2 blockade with trastuzumab and lapatinib yielded good response rates in HER2-amplified, RAS wild type, treatment-refractory metastatic colorectal cancer patients, according to results of the HERACLES study. (Source: CancerNetwork)
Source: CancerNetwork - April 19, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Conferences/AACR 2017 Colorectal Cancer Gastrointestinal Cancer News Source Type: news

Dexrazoxane Adds Cardioprotective Effect in HER2-Positive Breast Cancer
Administration of dexrazoxane along with adjuvant chemotherapy was cardioprotective in patients with HER2-positive breast cancer treated with chemotherapy followed by 1 year of trastuzumab maintenance therapy. (Source: CancerNetwork)
Source: CancerNetwork - April 19, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer Cancer Complications HER2-Positive Breast Cancer News Source Type: news

Trastuzumab Disappoints in HER2-Positive Gastroesophageal Cancer Trastuzumab Disappoints in HER2-Positive Gastroesophageal Cancer
The HER2-targeted monoclonal antibody trastuzumab coupled with the tubulin inhibitor emtansine is no better than taxane against previously treated, HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 17, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Mylan Deal Clears Path for Biosimilar Copy of Roche's Herceptin Mylan Deal Clears Path for Biosimilar Copy of Roche's Herceptin
Generic drugmaker Mylan said on Monday it had reached a settlement with Roche providing"a clear pathway" for the launch of its biosimilar version of the Swiss company's top-selling breast cancer drug Herceptin in major markets.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - March 14, 2017 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Mylan Announces Global Settlement and License Agreements with Genentech and Roche on Herceptin(R)
HERTFORDSHIRE, England and PITTSBURGH, March 13, 2017 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that Mylan has agreed to the terms of a global settlement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. ... Biopharmaceuticals, Oncology, Generics, Licensing Mylan, Genentech, Roche Group, Herceptin, trastuzumab, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 13, 2017 Category: Pharmaceuticals Source Type: news

Mylan reaches deal with Herceptin
Mylan NV announced Monday a deal with Genentech Inc. and F. Hoffmann-La Roche Ltd. that will clear the way for Mylan to launch its version of a drug to treat breast cancer. Financial terms of the deal between Mylan (Nasdaq: MYL) and Genentech and F. Hoffmann-La Roche weren't announced, although Mylan will receive a global license to launch trastuzumab, the generic name for Herceptin. It also will withdraw challenges to patents by Genentech. The license deal does not include Mexico, Brazil or Japan,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 13, 2017 Category: Pharmaceuticals Authors: Paul J. Gough Source Type: news

Can Less Costly 9-Week Trastuzumab Match Efficacy of 12-Month Regimen?
A cost-effectiveness analysis found that 9 weeks of trastuzumab therapy is better than the more standard 12 months in patients with HER2-positive breast cancer, without loss of clinical efficacy. (Source: CancerNetwork)
Source: CancerNetwork - March 8, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Practice & Policy Source Type: news